MetaCap

Nuvectis Pharma (NVCT) vs Sagimet Biosciences Series A (SGMT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nuvectis Pharma (NVCT) has outperformed Sagimet Biosciences Series A (SGMT) over the past year, gaining 218.9% versus a gain of 36.1%. Nuvectis Pharma is the larger company by market cap ($666.8 million vs $648.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NVCT+218.91%SGMT+36.13%
+389%+169%-52%
Nov 21, 20251 yearNov 20, 2026
NVCT+29.53%SGMT-43.07%
+90%-3%-95%
Jul 10, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NVCT versus SGMT key metrics
MetricNVCTSGMT
Share price$19.39$9.08
Market cap$666.80M$648.02M
1-day change-2.27%-5.61%
YTD return+156.82%+53.38%
1-year return+218.91%+36.13%
EPS (TTM)$-2.00$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-26.44M$-51.04M
52-week high$29.28$11.45
52-week low$5.77$4.50
Distance from 52-week high-33.77%-20.69%
Analyst consensusnonestrong_buy
Avg. price target upside+82.57%+200.33%
Average volume206.37K1.23M
Shares outstanding34.39M71.37M
Employees1916
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NVCT has outperformed SGMT by 182.8 percentage points over the past year.

About Nuvectis Pharma

NVCT stock →

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

About Sagimet Biosciences Series A

SGMT stock →

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

NVCT vs SGMT FAQ

Which is bigger, Nuvectis Pharma or Sagimet Biosciences Series A?

Nuvectis Pharma (NVCT) is larger, with a market capitalization of $666.80M compared with $648.02M for Sagimet Biosciences Series A (SGMT).

Which stock has performed better over the past year, NVCT or SGMT?

NVCT returned +218.91% over the past 12 months, compared with +36.13% for SGMT (price return, excluding dividends). Past performance does not predict future results.

Are Nuvectis Pharma and Sagimet Biosciences Series A in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons